A Randomized, Double-blind, Placebo-controlled, Sequential, Multiple Ascending Dose (MAD) Study Following Oral Administration in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380
Cascade Pharmaceuticals, Inc
Summary
A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.
Description
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C. Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg. The next higher dose cohort will be enrolled only after the prior dose cohort has been d…
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: 1. The participant provided signed and dated informed consent. 2. Male or female aged 18-65 years (inclusive). 3. Fasting LDL-C \>110 mg/dL (2.85 mmol/L) at screening. 4. Female participants must meet one of the following: 1. Postmenopausal status confirmed by follicle-stimulating hormone (FSH) testing, or 2. Surgically sterile (medically documented), or 3. If with childbearing potential, the participant must agree to use at least one highly effective contraceptive method in combination with an additional effective contraceptive method from study initiation until…
Interventions
- DrugCS060380
CS060380 is administered orally once daily (QD)
- DrugPlacebo
Matching placebo is administered orally once daily (QD)
Location
- Pharmaron Clinical Pharmacology Center (CPC), Inc.Baltimore, Maryland